drugset / Trial / NCT07663630

A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Weight Loss

NCT07663630 ↗

Phase 1 Not yet recruiting 80 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

Study to investigate the effect of ponsegromab on skeletal muscle mass and physical function in adult participants with non-small cell lung cancer associated cachexia.

Timeline

Start
2026-07-22
Primary completion
2028-02-02
Completion
2029-03-29

Drugs

EvaluationDrugModalityDoseRoute
Subject ponsegromab Monoclonal antibody 400 mg Subcutaneous